Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements

Simply Wall St.05-16

Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635667590?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-16 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635667590","market":"hk","top_or_hot":-1,"title":"Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements","media":"Simply Wall St.","content":"<div>\n<p>Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-huma/humacyte/news/humacyte-huma-valuation-check-as-q1-2026-losses-meet-cost-cu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-16 23:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-huma/humacyte/news/humacyte-huma-valuation-check-as-q1-2026-losses-meet-cost-cu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-huma/humacyte/news/humacyte-huma-valuation-check-as-q1-2026-losses-meet-cost-cu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-huma/humacyte/news/humacyte-huma-valuation-check-as-q1-2026-losses-meet-cost-cu","article_id":"2635667590","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-huma/humacyte/news/humacyte-huma-valuation-check-as-q1-2026-losses-meet-cost-cu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635667590","pubTimestamp":1778945775,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that could influence how investors view the stock.\nSee our latest analysis for Humacyte.\nThe share price has been volatile, with a 1 month share price return of 26.36% but a 1 year total shareholder return that is down 58.48%. This reflects shifting sentiment as investors weigh fresh capital raises,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HUMA":"Humacyte, Inc.","BK4563":"昨日强势股"},"translate_title":"Humacyte(HUMA)2026年第一季度亏损符合成本削减新领导层和全球协议的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":1.5},"content_text":"Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that could influence how investors view the stock. See our latest analysis for Humacyte. The share price has been volatile, with a 1 month share price return of 26.36% but a 1 year total shareholder return that is down 58.48%. This reflects shifting sentiment as investors weigh fresh capital raises, Nasdaq compliance risk, and upcoming clinical milestones. If Humacyte's story has you reassessing risk and opportunity in biotech, it can help to compare it with other early stage healthcare names using 32 healthcare AI stocks With Humacyte trading at US$0.93 after years of steep share price declines, recent cost cuts, fresh capital and upcoming Symvess trial data create a tension: is this a reset level, or is the market already discounting future growth? AdvertisementMost Popular Narrative: 95.9% Undervalued Humacyte's most followed narrative pegs Fair Value at $22.83 against a last close of $0.93, framing a wide gap investors will want to understand.  Growing adoption of Symvess in civilian trauma centers, supported by 92 hospitals already eligible to purchase and reports that most early customers are reordering, directly supports potential revenue growth as usage patterns deepen.  Read the complete narrative. There is a detailed playbook behind that Fair Value. It blends rapid revenue expansion assumptions with a sharp swing in margins and a very different earnings profile. Curious which projections matter most and how they stack up against today. Result: Fair Value of $22.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the bullish story also leans heavily on Symvess adoption and dialysis trial progress, where slower uptake or regulatory setbacks could quickly challenge those optimistic assumptions. Find out about the key risks to this Humacyte narrative. Next Steps With sentiment clearly split between risk and reward, now is the moment to look through the underlying data yourself and stress test the assumptions behind both sides. To see how the current thesis balances upside potential with issues investors are worried about, review the 1 key reward and 5 important warning signs Looking for more investment ideas? If Humacyte has sharpened your focus on risk and reward, now is the time to widen your lens and line up a few backup options.  Target potential bargains by scanning for companies that look mispriced on fundamentals using the 50 high quality undervalued stocks. Protect your downside by filtering for businesses that score well on financial strength with the 66 resilient stocks with low risk scores. Get ahead of the crowd by spotting earlier stage opportunities in the screener containing 22 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Humacyte might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635667590","isCrawlerRequest":true}